NTRA
August 7, 2025 - AI Summary
Overvalued by 196.2% based on the discounted cash flow analysis.
Market cap | $22.97 Billion |
---|---|
Enterprise Value | $22.19 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $-1.53 |
Beta | 1.74 |
Outstanding Shares | 136,388,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -90.13 |
---|---|
PEG | -53.2 |
Price to Sales | 11.95 |
Price to Book Ratio | 18.59 |
Enterprise Value to Revenue | 11.29 |
Enterprise Value to EBIT | -81.57 |
Enterprise Value to Net Income | -88 |
Total Debt to Enterprise | 0.01 |
Debt to Equity | 0.17 |
No data
No data
Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operat...